Category Archives: Stell Cell Research


BMC Veterinary Research | All articles

All

Investigating the prevalence of Salmonella in dogs within the Midlands region of the United Kingdom

Preena Lowden, Corrin Wallis, Nancy Gee, Anthony Hilton BMC Veterinary Research 2015, 11:239 (17 September 2015)

Abstract | Full text | PDF | PubMed

Evaluation of inhibition of F4ac positive Escherichia coli attachment with xanthine dehydrogenase, butyrophilin, lactadherin and fatty acid binding protein

Predrag Novakovic, Chandrashekhar Charavaryamath, Igor Moshynskyy, Betty Lockerbie, Radhey Kaushik, Matthew Loewen, Beverly Kidney, Chris Stuart, Elemir Simko BMC Veterinary Research 2015, 11:238 (15 September 2015)

Abstract | Full text | PDF | ePUB | PubMed

Saliva as an alternative specimen for detection of Schmallenberg virus-specific antibodies in bovines

Justas Lazutka, Aliona Spakova, Vilimas Sereika, Raimundas Lelesius, Kestutis Sasnauskas, Rasa Petraityte-Burneikiene BMC Veterinary Research 2015, 11:237 (15 September 2015)

Abstract | Full text | PDF | PubMed

Veterinary homeopathy: Systematic review of medical conditions studied by randomised trials controlled by other than placebo

Robert T Mathie, Jrgen Clausen BMC Veterinary Research 2015, 11:236 (15 September 2015)

Abstract | Full text | PDF | PubMed

Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors

Michle Spoerri, Franco Guscetti, Sonja Hartnack, Alois Boos, Christine Oei, Orsolya Balogh, Renata M Nowaczyk, Erika Michel, Iris M Reichler, Mariusz P Kowalewski BMC Veterinary Research 2015, 11:235 (15 September 2015)

Abstract | Full text | PDF | PubMed

S100A12 concentrations and myeloperoxidase activity in the intestinal mucosa of healthy dogs

Mohsen Hanifeh, Romy Heilmann, Satu Sankari, Minna Rajamki, Laura Mkitalo, Pernilla Syrj, Susanne Kilpinen, Jan Suchodolski, Jrg Steiner, Thomas Spillmann BMC Veterinary Research 2015, 11:234 (14 September 2015)

Abstract | Full text | PDF | PubMed

Validity and practical utility of accelerometry for the measurement of in-hand physical activity in horses

R. Morrison, D. Sutton, C. Ramsoy, N. Hunter-Blair, J. Carnwath, E. Horsfield, P. Yam BMC Veterinary Research 2015, 11:233 (11 September 2015)

Abstract | Full text | PDF | PubMed

Induction of ROS generation and NF-B activation in MARC-145 cells by a novel porcine reproductive and respiratory syndrome virus in Southwest of China isolate

Yulin Yan, Aiguo Xin, Qian Liu, Hui Huang, Zhiyong Shao, Yating Zang, Ling Chen, Yongke Sun, Hong Gao BMC Veterinary Research 2015, 11:232 (10 September 2015)

Abstract | Full text | PDF | PubMed

Evaluation of eating and rumination behaviour in 300 cows of three different breeds using a noseband pressure sensor

Ueli Braun, Susanne Zrcher, Michael Hssig BMC Veterinary Research 2015, 11:231 (4 September 2015)

Abstract | Full text | PDF | PubMed

Peroxisome proliferator activated receptor protein expression is asymmetrically distributed in primary lung tumor and metastatic to lung osteosarcoma samples and does not correlate with gene methylation

Chamisa Herrera, Dae Kim, Senthil Kumar, Jeffrey Bryan BMC Veterinary Research 2015, 11:230 (4 September 2015)

Abstract | Full text | PDF | PubMed

Post mortem computed tomography and core needle biopsy in comparison to autopsy in eleven bernese mountain dogs with histiocytic sarcoma

Franziska Hostettler, Dominique Wiener, Monika Welle, Horst Posthaus, Urs Geissbhler BMC Veterinary Research 2015, 11:229 (2 September 2015)

Abstract | Full text | PDF | PubMed

Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up

Chris Rundfeldt, Andrea Tipold, Wolfgang Lscher BMC Veterinary Research 2015, 11:228 (2 September 2015)

Abstract | Full text | PDF | PubMed

Ultrasonographic examination of the spinal cord and collection of cerebrospinal fluid from the atlanto-occipital space in cattle

Ueli Braun, Jeannette Attiger, Carina Brammertz BMC Veterinary Research 2015, 11:227 (2 September 2015)

Abstract | Full text | PDF | PubMed

Screening anthelmintic resistance to triclabendazole in Fasciola hepatica isolated from sheep by means of an egg hatch assay

David Robles-Prez, Jos Martnez-Prez, Francisco Rojo-Vzquez, Mara Martnez-Valladares BMC Veterinary Research 2015, 11:226 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets

Thierry Olivry, Ralf Mueller, Pascal Prlaud BMC Veterinary Research 2015, 11:225 (28 August 2015)

Abstract | Full text | PDF | PubMed

International veterinary epilepsy task force recommendations for systematic sampling and processing of brains from epileptic dogs and cats

Kaspar Matiasek, Mart Pumarola i Batlle, Marco Rosati, Francisco Fernndez-Flores, Andrea Fischer, Eva Wagner, Mette Berendt, Sofie Bhatti, Luisa De Risio, Robyn Farquhar, Sam Long, Karen Muana, Edward Patterson, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Heidrun Potschka, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger Volk BMC Veterinary Research 2015, 11:216 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Force recommendations for a veterinary epilepsy-specific MRI protocol

Clare Rusbridge, Sam Long, Jelena Jovanovik, Marjorie Milne, Mette Berendt, Sofie Bhatti, Luisa De Risio, Robyn Farqhuar, Andrea Fischer, Kaspar Matiasek, Karen Muana, Edward Patterson, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Heidrun Potschka, Veronika Stein, Andrea Tipold, Holger Volk BMC Veterinary Research 2015, 11:194 (28 August 2015)

Abstract | Full text | PDF | PubMed

International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals

Mette Berendt, Robyn Farquhar, Paul Mandigers, Akos Pakozdy, Sofie Bhatti, Luisa De Risio, Andrea Fischer, Sam Long, Kaspar Matiasek, Karen Muana, Edward Patterson, Jacques Penderis, Simon Platt, Michael Podell, Heidrun Potschka, Mart Pumarola, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger Volk BMC Veterinary Research 2015, 11:182 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy

Heidrun Potschka, Andrea Fischer, Wolfgang Lscher, Ned Patterson, Sofie Bhatti, Mette Berendt, Luisa De Risio, Robyn Farquhar, Sam Long, Paul Mandigers, Kaspar Matiasek, Karen Muana, Akos Pakozdy, Jacques Penderis, Simon Platt, Michael Podell, Clare Rusbridge, Veronika Stein, Andrea Tipold, Holger A Volk BMC Veterinary Research 2015, 11:177 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe

Sofie Bhatti, Luisa De Risio, Karen Muana, Jacques Penderis, Veronika Stein, Andrea Tipold, Mette Berendt, Robyn Farquhar, Andrea Fischer, Sam Long, Wolfgang Lscher, Paul Mandigers, Kaspar Matiasek, Akos Pakozdy, Edward Patterson, Simon Platt, Michael Podell, Heidrun Potschka, Clare Rusbridge, Holger Volk BMC Veterinary Research 2015, 11:176 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Forces current understanding of idiopathic epilepsy of genetic or suspected genetic origin in purebred dogs

Velia-Isabel Hlsmeyer, Andrea Fischer, Paul Mandigers, Luisa DeRisio, Mette Berendt, Clare Rusbridge, Sofie Bhatti, Akos Pakozdy, Edward Patterson, Simon Platt, Rowena Packer, Holger Volk BMC Veterinary Research 2015, 11:175 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

International Veterinary Epilepsy Task Force consensus reports on epilepsy definition, classification and terminology, affected dog breeds, diagnosis, treatment, outcome measures of therapeutic trials, neuroimaging and neuropathology in companion animals

Holger Volk BMC Veterinary Research 2015, 11:174 (28 August 2015)

Full text | PDF | ePUB | PubMed

International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs

Luisa De Risio, Sofie Bhatti, Karen Muana, Jacques Penderis, Veronika Stein, Andrea Tipold, Mette Berendt, Robyn Farqhuar, Andrea Fischer, Sam Long, Paul Mandigers, Kaspar Matiasek, Rowena Packer, Akos Pakozdy, Ned Patterson, Simon Platt, Michael Podell, Heidrun Potschka, Mart Batlle, Clare Rusbridge, Holger Volk BMC Veterinary Research 2015, 11:148 (28 August 2015)

Abstract | Full text | PDF | ePUB | PubMed

BoHV-4 immediate early 1 gene is a dispensable gene and its product is not a bone marrow stromal cell antigen 2 counteracting factor

Valentina Franceschi, Antonio Capocefalo, Sarah Jacca, Alfonso Rosamilia, Sandro Cavirani, Fengwen Xu, Wentao Qiao, Gaetano Donofrio BMC Veterinary Research 2015, 11:224 (27 August 2015)

Abstract | Full text | PDF | PubMed

Update on epidemiology of canine babesiosis in Southern France

Magalie Ren-Martellet, Claire Moro, Jeanne Chne, Gilles Bourdoiseau, Luc Chabanne, Patrick Mavingui BMC Veterinary Research 2015, 11:223 (25 August 2015)

Abstract | Full text | PDF | PubMed

More:
BMC Veterinary Research | All articles

STAP cells | Knoepfler Lab Stem Cell Blog

Post navigation

For the past few years post-publication peer review (PPPR) has grown in influence and one particular website, PubPeer, has become the primary go-to place specifically for bluntPPPR. The kind that happens in journal clubs in labs across the world. Comments on PubPeer have led to numerous serious corrections and retractions of flawed articles. Im most familiar with its role in the STAP cell case.

Both the founders of and most of the commenters on PubPeer have remained anonymous.

That is until today.

The founders of PubPeer have publicly identified themselves in a blog post and formed a new non-profit organization, The PubPeer Foundation.

PubPeer founders include Brandon Stell, George Smith and Richard Smith. Also with the founders on the PubPeer Foundation Board of Directors will be Boris Barbour and Gabor Brasnjo.

Who are these guys?

RetractionWatch (big HT to them) has an interesting interview with PubPeer founder Stell. I highly recommend reading it. Jennifer Couzin-Frankel over at Science also has a nice piece on this development.

Stell is a neuroscientist and Co-Team Leader at the Brain Physiology Lab in Paris, the source of his picture above.

I was trying to learn more about the other two founders, George Smith and Richard Smith. From Couzin-Frankels piece it appears that the brothers want to remain relatively out of the limelight, and their very common names may very well aid them in that. Couzin-Frankel does write that Richard was a grad student who briefly worked in Stells lab and George is a web developer.

As to the Foundation, RetractionWatch has a helpful quote from Stell on looking ahead:

What role do you hope PubPeer plays moving forward? What plans do you have for the Foundation?

We hope that the PubPeer Foundation will provide us with more opportunities to develop the site in ways that will help grow the community of post-publication peer reviewers and further encourage quality science.As more of us scientists become accustomed to commenting on papers, and as that becomes more of a part of the overall scientific process, I think well be able to finally up-end the backwards reward structure that is currently in place in science. Hopefully we can get to a point where the data are much more important to a scientists career than the journal that published them.

To form the PubPeer Foundation, the leaders could not remain anonymous. It seems like a good thing that the founders of PubPeer have identified themselves. They deserve a lot of credit for having had a transformative impact on how science corrects itself. Theyve also faced tough situations such as being sued by Fazlul Sarkar, a case that is still working its way through the legal system. Sarkar wants to know the identity of some anonymous PubPeer commenters. I predict that the PubPeer Foundation will now receive substantial financial support, which in part can be used to get legal assistancefor possible future challenges.

PubPeer has grown quickly, now has a striking following with around 300,000 pageviews/month and contains 35,000 total comments.

Obokata late press conference

The Japanese public broadcasting system, NHK, has been accused by scientist Haruko Obokata of violating her human rights.

Obokata was the primary researcher involved in the STAP cell fiasco in which two ultimately retracted Nature papers contained duplicated, plagiarized, and manipulated data. She was certainly not the only researcher on those papers, but overall she has been accused of having the most central role in the STAP problems. Obokata left RIKEN late in 2014.

During the height of the STAP cell mess the Japanese media hounded Obokata and other STAP cell authors including Yoshiki Sasai, who ultimately committed suicide. From accounts in Japan, the STAP cell story was on the equivalent of the nightly news and on the front of national newspapers and tabloids almost every day for a time.

For instance, NHK was incredibly persistent with pursing Obokata and now Obokata has said that they violated her human rights in a complaint to the Japanese Broadcasting Ethics & Program Improvement Organization or BPO. Obokata asserts that NHK violated her rights in numerous ways including accusing her of stealing embryonic stem cells and she sustained injuries while being pursued by NHK. BPO will be investigating these and other assertions by Obokata against NHK.

During the STAP cell mess last year, it seems because I was covering the STAP cell claims and science here on this blog, many members of the Japanese media emailed and called me. I can understand that they were looking for information and perspectives, but it went out of control in certain cases. Some, including reporters saying they were from NHK, were very aggressive with me. They some persistently called me at work and even at home in the middle of the night.

I had decided to not talk with them because of their aggressiveness and their tendency to focus on negative, personal stories rather than the science and facts, but they wouldnt take no for an answer. Several pursued me for comment at conferences too. I dont have direct knowledge of what happened with Obokata and NHK, but my sense is that the media went way out of bounds on STAP and made it personal.

Who can forget the STAP cell scandal of last year?

Now almost a year and a half after the deeply flawed papers first were published, where do things stand?

As an international collaboration there were both American and Japanese sides to STAP.

In the US, STAP still remains eerily quiet.

In a month or so, the one-year sabbatical of STAP cell paper senior author, Professor Charles Vacanti of Brigham and Womens Hospital and Harvard Medical School, is scheduled to end.

There has been no public disclosure as to whether (or if) there was or is an institutional investigation into the possible roles of Vacanti and his trainee Koji Kojima in the fiasco that ultimately led to the retraction of two Nature papers.

In contrast, in Japan there have already been many serious repercussions for the STAP cell authors including Haruko Obokata, who was forced out of RIKEN after she couldnt reproduce STAP. See a full STAP cell timeline here.

Just recentlyit was announced that Obokata has been forced to repay the publication fees for the Nature papers. Not a big deal in it of itself, but still just another repercussion for her. The same article quoted an Obokata attorney that her physical condition is a concern.

Vacanti and Obokata

Overallthere has been and continues to be this tension between the reaction to STAP in the US and in Japan.

Well beyond Obokata, many other researchers in Japan have been negatively affected by the fallout from STAP. I dont think its an exaggeration to call it a scientific disaster. In the US, there has been pretty much no apparent fallout. Who knows, it may stay that way.

In the mean time the retracted STAP papers have become in a relatively short period extremely highly cited publications (e.g. 160 citations for one on GoogleScholar). A brief look makes clear that notall those citations are referring tothe papers as an example of what can go wrong either. Some are referring to the supposed science as if it was real, which is pretty sad.

We also never really did hear any meaningful discussion of STAP from Nature either. They pretty much sidestepped any responsibility. Hopefully they have brought online a more rigorous manuscript evaluation system like the one used by EMBO.

Brigham and Womens and Harvard face another stem cell hot potato in the controversy related to the work of cardiac stem cell researcher Piero Anversa. In that case the institution(s) did investigate and Anversa has sued them over how the investigation was handled. To my knowledge that situation remainsunresolved.

Could this other situation be a factor in how those two linked institutions viewSTAP? Again, for all we know there never was an investigation of Vacantis or Kojimas potential roles in STAP.

As more time passes, I dont think necessarily it means that the STAP issue will go away on this side of the world. Without more information on how the STAP storyevolvedhere in the US, it seems to me that the STAP issue overall cannot have full clarity and the lessons from it are incomplete. More facts and transparency on how that project developedare needed still. Will that ever happen? I dont know.

Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly some of them may have been more hopes than predictions.

At mid-year today on June 30th, how am I doing? See below. Note that of course for some the jury is still out.

BTW, stay tuned for more on an upcoming update on the Japan IPSC macular degeneration trial where there seems to have been a (hopefully minor) hitch.

The annual ISSCR meeting has started in Stockholm.

This is always a great annual meeting both for the science and for connecting with people including new friends and colleagues as well as old friends.

Another element to the meeting is the insider conversations in the halls, restaurants, and bars that tell a behind the scenes story of the stem cell field.

Beloware my top 10 things to look for that might be discussed over a beer or coffee this year.Also be sure to check out the wonderfulguide to Stockholm from Heather Main and if you are there at the meeting enter our stem cell contests to win up to $100.

See original here:
STAP cells | Knoepfler Lab Stem Cell Blog

Glutamate and glutamate receptors in the vertebrate retina …

Victoria Connaughton

1. General overview of synaptic transmission.

Cells communicate with each other electrically, through gap junctions, and chemically, using neurotransmitters. Chemical synaptic transmission allows nerve signals to be exchanged between cells which are electrically isolated from each other. The chemical messenger, or neurotransmitter, provides a way to send the signal across the extracellular space, from the presynaptic neuron to the postsynaptic cell. The space is called acleft and is typically more than 10 nanometers across. Neurotransmitters are synthesized in the presynaptic cell and stored in vesicles in presynaptic processes, such as the axon terminal. When the presynaptic neuron is stimulated, calcium channels open and the influx of calcium ions into the axon terminal triggers a cascade of events leading to the release of neurotransmitter. Once released, the neurotransmitter diffuses across the cleft and binds to receptors on the postsynaptic cell, allowing the signal to propagate. Neurotransmitter molecules can also bind onto presynaptic autoreceptors and transporters, regulating subsequent release and clearing excess neurotransmitter from the cleft. Compounds classified as neurotransmitters have several characteristics in common (reviewed in Massey, 1990, Erulkar, 1994). Briefly, (1) the neurotransmitter is synthesized, stored, and released from the presynaptic terminal. (2) Specific neurotransmitter receptors are localized on the postsynaptic cells, and (3) there exists a mechanism to stop neurotransmitter release and clear molecules from the cleft. Common neurotransmitters in the retina are glutamate, GABA, glycine, dopamine, and acetylcholine. Neurotransmitter compounds can be small molecules, such as glutamate and glycine, or large peptides, such as vasoactive intestinal peptide (VIP). Some neuroactive compounds are amino acids, which also have metabolic functions in the presynaptic cell.

Fig. 1. Structure of the glutamate molecule

Glutamate (Fig. 1) is believed to be the major excitatory neurotransmitter in the retina. In general, glutamate is synthesized from ammonium and alpha-ketoglutarate (a component of the Krebs Cycle) and is used in the synthesis of proteins, other amino acids, and even other neurotransmitters (such as GABA; Stryer, 1988). Though glutamate is present in all neurons, only a few are glutamatergic, releasing glutamate as their neurotransmitter. Neuroactive glutamate is stored in synaptic vesicles in presynaptic axon terminals (Fykse and Fonnum, 1996). Glutamate is incorporated into the vesicles by a glutamate transporter located in the vesicular membrane. This transporter selectively accumulates glutamate through a sodium-independent, ATP-dependent process (Naito and Ueda, 1983, Tabb and Ueda, 1991, Fykse and Fonnum, 1996), resulting in a high concentration of glutamate in each vesicle. Neuroactive glutamate is classified as an excitatory amino acid (EAA) because glutamate binding onto postsynaptic receptors typically stimulates, or depolarizes, the postsynaptic cells.

2. Histological techniques identify glutamatergic neurons.

Fig. 2. Glutamate immunoreactivity

Using immunocytochemical techniques, neurons containing glutamate are identified and labeled with a glutamate antibody. In the retina, photoreceptors, bipolar cells, and ganglion cells are glutamate immunoreactive (Ehinger et al, 1988, Marc et al., 1990, Van Haesendonck and Missotten, 1990, Kalloniatis and Fletcher, 1993, Yang and Yazulla, 1994, Jojich and Pourcho, 1996) (Fig. 2). Some horizontal and/or amacrine cells can also display weak labeling with glutamate antibodies (Ehinger et al., 1988, Marc et al., 1990, Jojich and Pourcho, 1996; Yang, 1996). These neurons are believed to release GABA, not glutamate, as their neurotransmitter (Yazulla, 1986), suggesting the weak glutamate labeling reflects the pool of metabolic glutamate used in the synthesis of GABA. This has been supported by the results from double-labeling studies using antibodies to both GABA and glutamate: glutamate-positive amacrine cells also label with the GABA antibodies (Jojich and Pourcho, 1996, Yang, 1996).

Fig. 3. Autoradiogram of glutamate uptake through glutamate transporters

Photoreceptors, which contain glutamate, actively take up radiolabeled glutamate from the extracellular space, as do Muller cells (Fig. 3) (Marc and Lam, 1981; Yang and Wu, 1997). Glutamate is incorporated into these cell types through a high affinity glutamate transporter located in the plasma membrane. Glutamate transporters maintain the concentration of glutamate within the synaptic cleft at low levels, preventing glutamate-induced cell death (Kanai et al., 1994). Though Muller cells take up glutamate, they do not label with glutamate antibodies (Jojich and Pourcho, 1996). Glutamate incorporated into Muller cells is rapidly broken down into glutamine, which is then exported from glial cells and incorporated into surrounding neurons (Pow and Crook, 1996). Neurons can then synthesize glutamate from glutamine (Hertz, 1979, Pow and Crook, 1996).

Thus, histological techniques are used to identify potential glutamatergic neurons by labeling neurons containing glutamate (through immunocytochemistry) and neurons that take up glutamate (through autoradiography). To determine if these cell types actually release glutamate as their neurotransmitter, however, the receptors on postsynaptic cells have to be examined.

3. Glutamate receptors.

Once released from the presynaptic terminal, glutamate diffuses across the cleft and binds onto receptors located on the dendrites of the postsynaptic cell(s). Multiple glutamate receptor types have been identified. Though glutamate will bind onto all glutamate receptors, each receptor is characterized by its sensitivity to specific glutamate analogues and by the features of the glutamate-elicited current. Glutamate receptor agonists and antagonists are structurally similar to glutamate (Fig. 4), which allows them to bind onto glutamate receptors. These compounds are highly specific and, even in intact tissue, can be used in very low concentrations because they are poor substrates for glutamate uptake systems (Tachibana and Kaneko, 1988, Schwartz and Tachibana, 1990).

Fig. 4. Glutamate receptor agonists and antagonists

Two classes of glutamate receptors (Fig. 5) have been identified: (1) ionotropic glutamate receptors, which directly gate ion channels, and (2) metabotropic glutamate receptors, which may be coupled to an ion channel or other cellular functions via an intracellular second messenger cascade. These receptor types are similar in that they both bind glutamate and glutamate binding can influence the permeability of ion channels. However, there are several differences between the two classes.

Fig. 5. Ionotropic and metabotropic glutamate receptors and channels

4. Ionotropic glutamate receptors.

Glutamate binding onto an ionotropic receptor directly influences ion channel activity because the receptor and the ion channel form one complex (Fig. 5a). These receptors mediate fast synaptic transmission between neurons. Each ionotropic glutamate receptor, or iGluR, is formed from the co-assembly of individual subunits. The assembled subunits may or may not be homologous, with the different combinations of subunits resulting in channels with different characteristics (Keinanen et al., 1990, Verdoorn et al., 1991, Moyner et al., 1992; Nakanishi, 1992, Ozawa and Rossier, 1996).

Fig. 6. Comparison between NMDA and non-NMDA receptors

Two iGluR types (see Fig. 6) have been identified: (1) NMDA receptors, which bind glutamate and the glutamate analogue N-Methyl-D-Aspartate (NMDA) and (2) non-NMDA receptors, which are selectively agonized by kainate, AMPA, and quisqualate, but not NMDA.

Non-NMDA receptors. Glutamate binding onto a non-NMDA receptor opens non-selective cation channels more permeable to sodium (Na+) and potassium (K+) ions than calcium (Ca+2) (Mayer and Westbrook, 1987). Glutamate binding elicits a rapidly activating inward current at membrane potentials negative to 0 mV, and an outward current at potentials positive to 0 mV. Kainate, quisqualate, and AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) are the specific agonists at these receptors; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), NBQX (1,2,3,4-tetrahydro-6-nitro-2,3-dione-benzo[f]quinoxaline-7-sulfonamide), and DNQX (6,7-dinitroquinoxaline-2,3-dione) are the antagonists.

Fig. 7. Whole-cell patch clamp to show quisqualate and kainate gated currents

In retina, non-NMDA receptors have been identified on horizontal cells, OFF-bipolar cells, amacrine cells, and ganglion cells (see below). Patch clamp recordings (Gilbertson et al., 1991, Zhou et al., 1993, Boos et al., 1993, Cohen and Miller, 1994, Yu and Miller, 1995) indicate that AMPA, quisqualate, and/or kainate application can evoke currents in these cells. However, the kinetics of the ligand-gated currents differ. AMPA and quisqualate-elicited currents rapidly desensitize; whereas, kainate-gated currents do not (Fig. 7a). The desensitization at AMPA/quisqualate receptors can be reduced (Fig. 7b) by adding cyclothiazide (Yamada and Tang, 1993), which stabilizes the receptor in an active (or non-desensitized) state (Yamada and Tang, 1993, Kessler et al., 1996).

Each non-NMDA receptor is formed from the co-assembly of several subunits (Boulter et al., 1990, Nakanishi et al., 1990, Nakanishi, 1992). To date, seven subunits (named GluR1 through GluR7) have been cloned (Hollmann et al., 1989, Boulter et al., 1990, Keinanen et al., 1990, Nakanishi et al., 1990, Bettler et al., 1990, 1992, Egebjerg et al., 1991). Expression of subunit clones in Xenopus oocytes revealed that GluR5, GluR6, and GluR7 (along with subunits KA1 and KA2) co-assemble to form kainate(-preferring) receptors; whereas, GluR1, GluR2, GluR3, and GluR4 are assembled into AMPA(-preferring) receptors (Nakanishi, 1992).

NMDA receptors. Glutamate binding onto an NMDA receptor also opens non-selective cation channels, resulting in a conductance increase. However, the high conductance channel associated with these receptors is more permeable to Ca+2 than Na+ ions (Mayer and Westbrook, 1987) and NMDA-gated currents typically have slower kinetics than kainate- and AMPA-gated channels. As the name suggests, NMDA is the selective agonist at these receptors. The compounds MK-801, AP-5 (2-amino-5-phosphonopentanoic acid), and AP-7 (2-amino-7-phosphoheptanoic acid) are NMDA receptor antagonists.

NMDA receptors are structurally complex, with separate binding sites for glutamate, glycine, magnesium ions (Mg+2), zinc ions (Zn+2), and a polyamine recognition site (Fig. 6b). There is also an antagonist binding site for PCP and MK-801 (Lodge, 1997). The glutamate, glycine, and magnesium binding sites are important for receptor activation and gating of the ion channel. In contrast, the zinc and polyamine sites are not needed for receptor activation, but affect the efficacy of the channel. Zinc blocks the channel in a voltage-independent manner (Westbrook and Mayer, 1987). The polyamine site (Ransom and Stec, 1988, Williams et al., 1994) binds compounds such as spermine or spermidine, either potentiating (Ranson and Stec, 1988; Williams et al., 1994) or inhibiting (Williams et al., 1994) the activity of the receptor, depending on the combination of subunits forming each NMDA receptor (Williams et al., 1994).

To date, five subunits (NR1, NR2a, N2b, N2c, and N2d) of NMDA receptors have been cloned (Moriyoshi et al., 1991, Ikeda et al., 1992, Katsuwada et al., 1992, Meguro et al., 1992, Ishii et al., 1993). As with non-NMDA receptors, NMDA receptor subunits can co-assemble as homomers (i.e., five NR1 subunits; Moyner et al., 1992, Moriyoshi et al., 1992) or heteromers (one NR1 + four NR2 subunits; Meguro et al., 1992, Katsuwada et al., 1992, Moyner et al., 1992, Ishii et al., 1993). However, all functional NMDA receptors express the NR1 subunit (Moyner et al., 1992, Nakanishi, 1992, Ishii et al., 1993).

Fig. 8. NMDA receptor activation

The glutamate, glycine, and Mg+2 binding sites confer both ligand-gated and voltage-gated properties onto NMDA receptors. NMDA receptors are ligand-gated because the binding of glutamate (ligand) is required to activate the channel. In addition, micromolar concentrations of glycine must also be present (Fig. 8) (Johnson and Ascher, 1987, Kleckner and Dingledine, 1988). The requirement for both glutamate and glycine makes them co-agonists (Kleckner and Dingledine, 1988) at NMDA receptors.

Mg+2 ions provide a voltage-dependent block of NMDA-gated channels (Nowak et al., 1984). This can be seen in the current-voltage (I-V) relationship presented in Fig. 9 (from Nowak et al., 1984).

Fig. 9. Mg+2 ions block NMDA receptor channels

I-V curves plotted from currents recorded in the presence of Mg+2 have a characteristic J-shape (dotted line); whereas, a linear relationship is calculated in Mg+2-free solutions (solid line). At negative membrane potentials, Mg+2 ions occupy the binding site causing less current to flow through the channel. As the membrane depolarizes, the Mg+2 block is removed (Nowak et al., 1984).

Retinal ganglion cells and some amacrine cell types express functional NMDA receptors in addition to non-NMDA receptors (i.e., Massey and Miller, 1988, 1990, Mittman et al., 1990, Dixon and Copenhagen 1992, Diamond and Copenhagen, 1993, Cohen and Miller, 1994). The currents elicited through these different iGluR types can be distinguished pharmacologically. Non-NMDA receptor antagonists block a transient component of the ganglion cell light response; whereas, NMDA receptor antagonists block a more sustained component (Mittman et al., 1990, Diamond and Copenhagen, 1993, Hensley et al., 1993, Cohen and Miller, 1994). These findings suggest the currents elicited through co-localized NMDA and non-NMDA receptors mediate differential contributions to the ON- and OFF-light responses observed in ganglion cells (i.e., Diamond and Copenhagen, 1993).

5. Metabotropic glutamate receptors.

Unlike ionotropic receptors, which are directly linked to an ion channel, metabotropic receptors are coupled to their associated ion channel through a second messenger pathway. Ligand (glutamate) binding activates a G-protein and initiates an intracellular cascade (Nestler and Duman, 1994). Metabotropic glutamate receptors (mGluRs) are not co-assembled from multiple subunits, but are one polypeptide (Fig. 5b). To date, eight mGluRs (mGluR1-mGluR8) have been cloned (Houamed et al., 1991, Masu et al., 1991, Abe et al., 1992, Tanabe et al., 1992, Nakajima et al., 1993, Saugstad et al., 1994, Duvoisin et al., 1995). These receptors are classified into three groups (I, II, and III) based on structural homology, agonist selectivity, and their associated second messenger cascade (Table 1, end of chapter) (reviewed in Nakanishi, 1994, Knopfel et al., 1995, Pin and Duvoisin, 1995, Pin and Bockaert, 1995).

In brief, Group I mGluRs (mGluR1 and mGluR5) are coupled to the hydrolysis of fatty acids and the release of calcium from internal stores. Quisqualate and trans-ACPD are Group I agonists. Group II (mGluR2 and mGluR3) and Group III (mGluRs 4, 6, 7, and 8) receptors are considered inhibitory because they are coupled to the downregulation of cyclic nucleotide synthesis (Pin and Duvoisin, 1995). L-CCG-1 and trans-ACPD agonize Group II receptors; L-AP4 (also called APB) selectively agonizes Group III receptors. In situ hybridization studies have revealed that the mRNAs encoding Group I, II, and III mGluRs are present in retina (see below); however, with the exception of the APB receptor, the function of all these receptor types in retina has not been characterized.

APB receptor. In contrast to non-NMDA and NMDA receptors, glutamate binding onto an APB receptor elicits a conductance decrease (Slaughter and Miller, 1981, Nawy and Copenhagen, 1987, 1990) due to the closure of cGMP-gated non-selective cation channels (Nawy and Jahr, 1990) (Fig. 10).

Fig. 10.Whole-cell current traces to show kinetics of APB receptor gated currents

APB application selectively blocks the ON-pathway in the retina (Fig. 11) (Slaughter and Miller, 1981), i.e., ON-bipolar cell responses and the ON-responses in amacrine cells (Taylor and Wassle, 1995) and ganglion cells (Cohen and Miller, 1994, Kittila and Massey, 1995, Jin and Brunken, 1996) are eliminated by APB. Experimental evidence (Slaughter and Miller 1981, Massey et al., 1983) suggests the APB receptor is localized to ON-bipolar cell dendrites. Inhibition of amacrine and ganglion cell light responses, therefore, is due to a decrease in the input from ON-bipolar cells, not a direct effect on postsynaptic receptors.

Fig. 11. Intracellular recordings to show that APB selectively antagonizes the ON-pathways

APB (2-amino-4-phosphobutyric acid, also called L-AP4) is the selective agonist for all Group III mGluRs (mGluR4, 6, 7, and 8). So, which is the APB receptor located on ON-bipolar cell dendrites? MGluR4, 7, and 8 expression has been observed in both the inner nuclear layer and the ganglion cell layer (Duvoisin et al., 1995, Hartveit et al., 1995) suggesting these mGluRs are associated with more than one cell type. In contrast, mGluR6 expression has been localized to the INL (Nakajima et al., 1993, Hartveit et al., 1995) and the OPL (Nomura et al., 1994) where bipolar cell somata and dendrites are located. Furthermore, ON-responses are abolished in mice lacking mGluR6 expression (Masu et al., 1995). These mutants also display abnormal ERG b-waves, suggesting an inhibition of the ON-retinal pathway at the level of bipolar cells (Masu et al., 1995). Taken together, these findings suggest the APB receptor on ON-bipolar cells is mGluR6.

6. Glutamate transporters and transporter-like receptors.

Glutamate transporters have been identified on photoreceptors (Marc and Lam, 1981, Tachibana and Kaneko, 1988, Eliasof and Werblin, 1993) and Muller cells (Marc and Lam, 1981, Yang and Wu, 1997). From glutamate labeling studies, the average concentration of glutamate in photoreceptors, bipolar cells, and ganglion cells is 5mM (Marc et al. 1990). Physiological studies using isolated cells indicate that only M levels of glutamate are required to activate glutamate receptors (i.e., Aizenman et al., 1988, Zhou et al., 1993, Sasaki and Kaneko, 1996). Thus, the amount of glutamate released into the synaptic cleft is several orders of magnitude higher than the concentration required to activate most postsynaptic receptors. High affinity glutamate transporters located on adjacent neurons and surrounding glial cells rapidly remove glutamate from the synaptic cleft to prevent cell death (Kanai et al., 1994). Five glutamate transporters, EAAT-1 (or GLAST), EAAT-2 (or GLT-1), EAAT-3 (or EAAC-1), EAAT-4, and EAAT-5, have been cloned (Kanai and Hediger, 1992, Pines et al., 1992, Fairman et al., 1995, Schultz and Stell, 1996, Arriza et al., 1997, Kanai et al., 1997).

Glutamate transporters are pharmacologically distinct from both iGluRs and mGluRs. L-glutamate, L-aspartate, and D-aspartate are substrates for the transporters (Brew and Attwell, 1987, Tachibana and Kaneko, 1988, Eliasof and Werblin, 1993); glutamate receptor agonists (Brew and Attwell, 1987, Tachibana and Kaneko, 1988, Schwartz and Tachibana, 1990, Eliasof and Werblin, 1993) and antagonists (Barbour et al., 1991, Eliasof and Werblin, 1993) are not. Glutamate uptake can be blocked by the transporter blockers dihydrokainate (DHKA) and DL-threo-beta-hydroxyaspartate (HA) (Barbour et al., 1991, Eliasof and Werblin 1993).

Fig. 12 Glutamate transporters in Muller cells are electrogenic

Glutamate transporters incorporate glutamate into Muller cells along with the co-transport of three Na+ ions (Brew and Attwell, 1987, Barbour et al., 1988) and the antiport of one K+ ion (Barbour et al., 1988, Bouvier et al., 1992) and either one OH- or one HCO3- ion (Bouvier et al., 1992) (Fig. 12). The excess sodium ions generate a net positive inward current which drives the transporter (Brew and Attwell, 1987, Barbour et al., 1988). More recent findings indicate a glutamate-elicited chloride current is also associated with some transporters (Eliasof and Jahr, 1996, Arriza et al., 1997).

It should be noted that the glutamate transporters located in the plasma membrane of neuronal and glial cells (discussed in this section) are different from the glutamate transporters located on synaptic vesicles within presynaptic terminals (see section 1). The transporters in the plasma membrane transport glutamate in a Na+- and voltage-dependent manner independent of chloride (Brew and Attwell, 1987, Barbour et al., 1988, Kanai et al., 1994). L-glutamate, L-aspartate, and D-aspartate are substrates for these transporters (i.e., Brew and Attwell, 1987). In contrast, the vesicular transporter selectively concentrates glutamate into synaptic vesicles in a Na+-independent, ATP-dependent manner (Naito and Ueda, 1983, Tabb and Ueda, 1991, Fykse and Fonnum, 1996) that requires chloride (Tabb and Ueda, 1991, Fykse and Fonnum, 1996).

Glutamate receptors with transporter-like pharmacology have been described in photoreceptors (Picaud et al., 1995a, b, Grant and Werblin, 1996) and ON-bipolar cells (Grant and Dowling 1995, 1996). These receptors are coupled to a chloride current. The pharmacology of these receptors is similar to that described for glutamate transporters, as the glutamate-elicited current is (1) dependent upon external Na+, (2) reduced by transporter blockers, and (3) insensitive to glutamate agonists and antagonists. However, altering internal Na+ concentration does not change the reversal potential (Picaud et al., 1995b) or the amplitude (Grant and Werblin, 1995, Grant and Dowling, 1996) of the glutamate-elicited current, suggesting the receptor is distinct from glutamate transporters. At the photoreceptor terminals, the glutamate-elicited chloride current may regulate membrane potential and subsequent voltage-gated channel activity (i.e., Picaud et al., 1995a). Postsynaptically, this receptor is believed to mediate conductance changes underlying photoreceptor input to ON- cone bipolar cells (Grant and Dowling, 1995).

7. Localization of glutamate receptor types in the retina.

Fig. 13. The types of neurons in the vertebrate retina

Photoreceptor, bipolar, ganglion cells comprise the vertical transduction pathway in the retina. This pathway is modulated by lateral inputs from horizontal cells in the distal retina and amacrine cells in the proximal retina (Fig. 13). As described in the previous sections, photoreceptor, bipolar, and ganglion cells show glutamate immunoreactivity. Glutamate responses have been electrically characterized in horizontal and bipolar cells, which are postsynaptic to photoreceptors, and in amacrine and ganglion cells, which are postsynaptic to bipolar cells. Taken together, these results suggest glutamate is the neurotransmitter released by neurons in the vertical pathway. Recent in situ hybridization and immunocytochemical studies have localized the expression of iGluR subunits, mGluRs, and glutamate transporter proteins in the retina. These findings are summarized below.

8. Retinal neurons expressing ionotropic glutamate receptors.

In both higher and lower vertebrates, electrophysiological recording techniques have identified ionotropic glutamate receptors on the neurons comprising the OFF-pathway (Table 2, end of chapter). In the distal retina, OFF-bipolar cells (Fig. 14) (Euler et al., 1996, Sasaki and Kaneko, 1996, Hartveit, 1997) and horizontal cells (Fig. 15) (Yang and Wu, 1991, Zhou et al., 1993, Kriaj et al., 1994) respond to kainate, AMPA, and quisqualate application, but not NMDA nor APB. (However, NMDA receptors have been identified on catfish horizontal cells (ODell and Christensen, 1989, Eliasof and Jahr, 1997) and APB-induced hyperpolarizations have been reported in some fish horizontal cells (Nawy et al., 1989, Takahashi and Copenhagen, 1992, Furukawa et al., 1997)).

Non-NMDA agonists also stimulate both amacrine cells (Fig. 16a) (Massey and Miller, 1988, Dixon and Copenhagen, 1992, Boos et al., 1993) and ganglion cells (Fig. 16b) (Mittman et al., 1990, Diamond and Copenhagen, 1993, Hensley et al., 1993, Cohen and Miller, 1994, Yu and Miller, 1995). Ganglion cells responses to NMDA have been observed (Massey and Miller, 1988, 1990, Mittman et al., 1990, Diamond and Copenhagen, 1993, Cohen and Miller, 1994); whereas, NMDA responses have been recorded in only some types of amacrine cells (Massey and Miller, 1988, Dixon and Copenhagen, 1992, Boos et al., 1993, but see Hartveit and Veruki, 1997).

Fig. 16. Glutamate receptors on amacrine and ganglion cells

Consistent with this physiological data, antibodies to the different non-NMDA receptor subunits differentially label all retinal layers (Table 3, end of chapter; Hartveit et al., 1994, Peng et al., 1995, Hughes, 1997, Pourcho et al., 1997) and mRNAs encoding the different non-NMDA iGluR subunits are similarly expressed (Hughes et al., 1992, Hamassaki-Britto et al., 1993, Brandstatter et al., 1994). In contrast, mRNAs encoding NMDA subunits are expressed predominantly in the proximal retina, where amacrine and ganglion cells are located (INL, IPL, GCL; Table 3) (Brandstatter et al., 1994, Hartveit et al., 1994), though mRNA encoding the NR2a subunit (Hartveit et al., 1994) has been observed in the OPL and antibodies to the NR2d (Wenzel et al., 1997) and the NR1 subunits (Hughes, 1997) label rod bipolar cells.

9. Retinal neurons expressing metabotropic glutamate receptors.

All metabotropic glutamate receptors, except mGluR3, have been identified in retina either through antibody staining (Peng et al., 1995, Brandstatter et al., 1996, Koulen et al., 1997, Pourcho et al., 1997) or in situ hybridization (Nakajima et al., 1993, Duvoisin et al., 1995, Hartveit et al., 1995). MGluRs are differentially expressed throughout the retina, specifically in the outer plexiform layer, inner nuclear layer, inner plexiform layer, and the ganglion cell layer (Table 4, end of chapter). Though different patterns of mGluR expression have been observed in the retina, only the APB receptor on ON-bipolar cells has been physiologically examined.

10. Retinal neurons expressing glutamate transporters.

The glutamate transporters GLAST, EAAC1, and GLT-1have been identified in retina (Table 5, end of chapter). GLAST (L-glutamate/L-aspartatetransporter) immunoreactivity is found in all retinal layers (Otori et al. 1994), but not in neuronal tissue. GLAST is localized to Muller cell membranes (Otori et al. 1994, Derouiche and Rauen, 1995, Rauen et al., 1996, Lehre et al., 1997). In contrast, EAAC-1 (excitatoryaminoacidcarrier-1) antibodies do not label Muller cells or photoreceptors. EAAC-1 immunoreactivity is observed in ganglion and amacrine cells in chicken, rat, goldfish, and turtle retinas. In addition, bipolar cells positive labeled with EAAC-1 antibody in lower vertebrates and immunopositive horizontal cells were observed in rat (Schultz and Stell, 1996). GLT-1 (glutamatetransporter-1) proteins have been identified in monkey (Grunert et al., 1994), rat (Rauen et al., 1996), and rabbit (Massey et al., 1997) bipolar cells. In addition, a few amacrine cells were weakly labeled with the GLT-1 antibody in rat (Rauen et al., 1996), as were photoreceptor terminals in rabbit (Massey et al., 1997).

11. Summary and conclusions.

Fig. 17. The ribbon glutamatergic synapse in the retina

Histological analyses of presynaptic neurons and physiological recordings from postsynaptic cells suggest photoreceptor, bipolar, and ganglion cells release glutamate as their neurotransmitter. Multiple glutamate receptor types are present in the retina. These receptors are pharmacologically distinct and differentially distributed. IGluRs directly gate ion channels and mediate rapid synaptic transmission through either kainate/AMPA or NMDA receptors. Glutamate binding onto iGluRs opens cation channels, depolarizing the postsynaptic cell membrane. Neurons within the OFF-pathway (horizontal cells, OFF-bipolar cells, amacrine cells, and ganglion cells) express functional iGluRs. MGluRs are coupled to G-proteins. Glutamate binding onto mGluRs can have a variety of effects depending on the second messenger cascade to which the receptor is coupled. The APB receptor, found on ON-bipolar cell dendrites, is coupled to the synthesis of cGMP. At these receptors, glutamate decreases cGMP formation leading to the closure of ion channels. Glutamate transporters, found on glial and photoreceptor cells, are also present at glutamatergic synapses (Fig. 17). Transporters remove excess glutamate from the synaptic cleft to prevent neurotoxicity. Thus, postsynaptic responses to glutamate are determined by the distribution of receptors and transporters at a glutamatergic synapses which, in retina, determine the conductance mechanisms underlying visual information processing within the ON- and OFF-pathways.

Tables

Link:
Glutamate and glutamate receptors in the vertebrate retina ...

Stem Cells to Treat Blindness – Understanding Stem Cell …

Author: Ian Murnaghan BSc (hons), MSc - Updated: 18 August 2015 | Comment

For people who are blind, the thought of a treatment to restore their sight may seem like an impossible dream. But it may eventually become a reality after scientists last year were able to restore the eyesight of a blind person. The treatment works by replacing those cells in the eye know as retinal cells that have been damaged or worn out from diseases such as macular degeneration. For the elderly in particular, macular degeneration is a common concern as it can lead to enormous loss of vision in one or both eyes.

When macular degeneration strikes, it affects the area of the eye that is important for allowing us to see fine details. The disease may progress very slowly so that a person barely notices any changes at all. Or, it might progress rapidly, causing significant vision loss.

Interestingly enough, previous studies using stem cells had failed to restore sight. One reason for the problem relates to the choice of stem cells. In the most recent study, researchers used stem cells that were more mature than the ones previous researchers had used. The choice proved successful as the stem cells developed into photoreceptors and were able to join with the nerves that lead to the brain.

Researchers hope to see these kinds of transplants happening on a greater scale in approximately ten years. With many patients suffering from diseases in the eye that cause photoreceptors to die, this research offers a way to provide photoreceptor transplantation, helping to restore eyesight for many people around the world. The use of a patient's own cells also avoids the potential for immunological rejection, a threat that comes with other types of treatment.

You might also like...

Leave a Comment, Ask for Advice or Share Your Story...

avi - Your Question:

My daughter problem is optic nerve damages by birth she is 11 yrars. Kindly advise as per given details. in possible stem cell therapy.

Our Response:

ExploreStemCells - 19-Aug-15 @ 12:18 PM

avi - 18-Aug-15 @ 4:09 PM

Creative Animodel - 12-Aug-15 @ 10:02 AM

aman - Your Question:

My dougter has cojenital flicum fold in retina, can stem cell cure her vission

Our Response:

ExploreStemCells - 11-Aug-15 @ 10:16 AM

aman - 8-Aug-15 @ 6:45 PM

david and son - 7-Aug-15 @ 1:47 AM

There is no one doing this in the UK currently, as it is still very much at the research stage of development. You may find certain other countries advertising fee-paying stem cell treatments for specific conditions. However, please be aware these treatments are not backed or endorsed by scientific evidence.

ExploreStemCells - 5-Aug-15 @ 2:03 PM

Brittany - 4-Aug-15 @ 8:09 AM

Lon - 29-Jul-15 @ 5:20 PM

Ceris - 21-Jul-15 @ 8:26 PM

ExploreStemCells - 22-Jun-15 @ 11:09 AM

ask - 19-Jun-15 @ 8:08 AM

savy - 18-Jun-15 @ 6:50 AM

sujal - 7-Jun-15 @ 1:46 PM

ward - 20-May-15 @ 8:56 PM

ExploreStemCells - 14-May-15 @ 12:59 PM

erin - 12-May-15 @ 7:06 PM

nil - 28-Apr-15 @ 12:15 PM

kev - 20-Apr-15 @ 8:04 AM

Gori ga - 14-Apr-15 @ 4:21 PM

ExploreStemCells - 8-Apr-15 @ 2:55 PM

Maggi - 6-Apr-15 @ 3:08 PM

Diamond - 25-Mar-15 @ 4:26 PM

Thara - 16-Feb-15 @ 7:53 PM

Imran - 13-Feb-15 @ 7:24 PM

ExploreStemCells - 12-Feb-15 @ 11:46 AM

annu - 11-Feb-15 @ 3:10 PM

Munna - 18-Jan-15 @ 4:09 PM

ExploreStemCells - 14-Jan-15 @ 11:04 AM

rita - 13-Jan-15 @ 5:42 PM

Title:

(never shown)

Read more here:
Stem Cells to Treat Blindness - Understanding Stem Cell ...

History of Stem Cell Research

Author: Ian Murnaghan BSc (hons), MSc - Updated: 6 July 2015 | Comment

Stem cells have an interesting history that has been somewhat tainted with debate and controversy. In the mid 1800s it was discovered that cells were basically the building blocks of life and that some cells had the ability to produce other cells.

Attempts were made to fertilise mammalian eggs outside of the human body and in the early 1900s, it was discovered that some cells had the ability to generate blood cells.

In 1968, the first bone marrow transplant was performed to successfully treat two siblings with severe combined immunodeficiency. Other key events in stem cell research include:

More recently, in 2005, scientists at Kingston University in England were purported to have found another category of stem cells. These were named cord blood embryonic-like stem cells, which originate in umbilical cord blood. It is suggested that these stem cells have the ability to differentiate into more cell types than adult stem cells, opening up greater possibilities for cell-based therapies. Then, in early 2007, researchers led by Dr. Anthony Atala claimed that a new type of stem cell had been isolated in amniotic fluid. This finding is particularly important because these stem cells could prove to be a viable alternative to the controversial use of embryonic stem cells.

Over the last few years, national policies and debate amongst the public as well as religious groups, government officials and scientists have led to various laws and procedures regarding stem cell harvesting, development and treatment for research or disease purposes. The goals of such policies are to safeguard the public from unethical stem cell research and use while still supporting new advancements in the field.

You might also like...

Leave a Comment, Ask for Advice or Share Your Story...

Jim - 6-Jul-15 @ 10:02 PM

Ramen Sarkar - 23-Jun-15 @ 9:46 AM

Ramen Sarkar - 18-Jun-15 @ 7:26 PM

tera baap - 17-May-15 @ 9:46 AM

almighty.king.jay - 25-Mar-15 @ 4:18 PM

Bobby - 1-Dec-14 @ 4:23 PM

Adil Ahmed 255 - 20-Nov-14 @ 10:48 AM

ExploreStemCells - 22-Oct-14 @ 2:18 PM

Yusuf Syed - 22-Oct-14 @ 1:30 PM

amaad - 22-Oct-14 @ 1:27 PM

dgdsfbgf - 22-Sep-14 @ 3:18 PM

coline - 9-Aug-14 @ 2:13 PM

Manoj Jain - 6-Jul-14 @ 9:35 AM

sri - 19-Mar-14 @ 7:13 PM

jimmy - 25-Feb-14 @ 3:19 PM

deedee - 24-Jan-14 @ 11:36 AM

arwa - 24-May-13 @ 4:39 PM

GINGERGIRL3 - 25-Nov-12 @ 1:04 AM

zeddiesty - 23-Oct-12 @ 4:40 AM

britishandproud - 29-May-12 @ 8:58 PM

VTP - 29-May-12 @ 7:01 PM

Biogirl - 12-Nov-11 @ 4:58 PM

Searcher - 5-May-11 @ 10:40 PM

Title:

(never shown)

See the rest here:
History of Stem Cell Research

Why I’m sure human stem cell trial will be safe – New …

(Image: Natasha Little)

The new kind of stem cell announced yesterday may be the future of regenerative medicine, but Masayo Takahashis pilot safety study using a type of stem cell to treat age-related blindness is at the cutting edge

Later this year, you will make history when you begin the first ever human trial of induced pluripotent stem cells. Why is this such a big deal? Stem cells have enormous medical potential because they can become any other type of cell. If we can use them to replace old or damaged cells, this could have huge implications for treating degenerative diseases.

Stem cells can be harvested from embryos, but this is ethically controversial. Despite this, there are several trials of these embryonic stem cells under way. Their use often requires drugs to stop the immune system from rejecting them, which can cause complications for elderly patients. Induced pluripotent stem (iPS) cells offer an alternative. These are made from a patients own cells, removing the need for the immunosuppressant drugs. Plus there are no ethical issues.

How would treatment with iPS cells work? iPS cells are made by injecting several reprogramming genes into adult cells that have been removed from the body. This makes them rewind to an embryonic state. Then, we can make iPS cells differentiate into the cell type we need by injecting proteins that instruct embryonic stem cells to become liver, retina or any other type of cell. The idea is that these reprogrammed cells can then be inserted in the body to replace damaged cells. We are at least 20 years from any clinical treatments, but the potential is exciting.

Are there any potential pitfalls with iPS cell treatments? Yes, we have to be very careful because iPS cells multiply endlessly. This means that if any undifferentiated iPS cells were accidentally put into someone, they could cause tumours. Thats why this study is so important. It is not a clinical trial, but a six-subject pilot study to confirm the safety of putting cells derived from iPS cells into humans.

Who are the participants in the study? The six people all have age-related macular degeneration in their eyes. This weakens the vision in the central field, eventually leaving people with only peripheral vision. In the type of degeneration we are working with, this is caused by the deterioration of the retinal pigment epithelium (RPE) the layer of cells that clears away extra-cellular debris that lands on the retina.

We aim to replace the damaged section of the RPE with cells created from skin taken from the patients arm. The skin cells will be reprogrammed into iPS cells and then differentiated into RPE cells. It will take a year to grow enough RPE cells to introduce them to a damaged eye. Although I am excited to see if there is any improvement in sight, this study aims only to demonstrate the safety of RPE cells derived from IPS cells.

How confident are you that the pilot will be a success? Very confident. We have trialled this intervention on mice, rats and monkeys, and observed no tumours. I chose to work with RPE cells because of their characteristic brown pigment. This means we can avoid injecting tumour-causing iPS cells by selecting only the clumps of pure brown RPE cells. Of course, we do have to pick out around 50,000 RPE cells, so it can be a bit tough.

Read the original here:
Why I'm sure human stem cell trial will be safe - New ...

Arguments Against Embryonic Stem Cell Research – Stem …

An embryo is actually a human; it should be valued as highly as a human life.

The reasoning can be summed up by the fact that, once an egg is fertilized, unless inhibited, it will develop into a fully-developed adult. This opinion is often related to religious doctrines which assert that conception marks the beginning of human life or the presence of a soul.

Viability is another standard under which embryos and fetuses have been regarded as human lives. In the United States, the 1973 Supreme Court case of Roe v. Wade concluded that viability determined the permissibility of abortions performed for reasons other than the protection of the woman's health, defining viability as the point at which a fetus is "potentially able to live outside the mother's womb, albeit with artificial aid."

The point of viability was 24 to 28 weeks when the case was decided and has since moved to about 22 weeks due to advancement in medical technology.

If further technological advances allow a sperm and egg to be combined and fully developed completely outside of the womb, an embryo will be viable as soon as it is conceived, and under the viability standard, life will begin at conception.

Embryonic stem cells should be abandoned in favor of alternatives, such as those involving adult stem cells.

This argument is used by opponents of embryonic destruction as well as researchers specializing in adult stem cell research. It is often claimed by pro-life supporters that the use of adult stem cells from sources such as umbilical cord blood has consistently produced more promising results than the use of embryonic stem cells.

Furthermore, adult stem cell research may be able to make greater advances if less money and resources were channeled into embryonic stem cell research. Adult stem cells have already produced therapies, while embryonic stem cells have not.

Here is the original post:
Arguments Against Embryonic Stem Cell Research - Stem ...

STEM CELL THERAPY IN BANGKOK – Andrew Drummond

He is a gifted speaker and recently targeted audiences have included readers of the Pattaya People newspaper and today it seems the Pattaya Expats Club run by controversial Pattaya People Media CEO Niels Colov. But listeners should always be cautious when it comes to stell cell treatment, a speciality of Dr. Richard DeAndrea.

No stem cell treatments (except hematopoietic stem cell transplantation) have been given approval by the U.S. Federal Drug Aministration, which means that they have not been tested for safety or for efficacy.

Although Dr. DeAndrea appears to be a highly qualified doctor, controversy still rages worldwide over stem cell therapy. Research is still in progress but there seems little doubt that the discovery of stem cells and what they could be potentially used for will be of great benefit.

Indeed the The U.S. National Institutes of Health's Guidelines has stated:

Dr Richard DeAndrea, MD, ND, also recently addressed the American Academy of Anti-Aging Medicine (A4M) Conference.

A4M is not recognised by the American Medical Association and critics have accused the group of using misleading marketing to sell expensive and ineffective products. This is not something I am accusing Dr. DeAndrea of doing.

But GSCN in Bangkok, for whom Dr. DeAndrew works, is offering Stem Cell therapy as a cure for multiple conditons.

Recently CBS 60 Minutes exposed a doctor who offered stem cell therapy for cerebral palsy when there was no research justifying its use. The programme makers also exposed other sharks in the industry. Stems cell therapy is not yet the Holy Grail or elixir of life.

Stem cell therapy treatments have been offered in Bangkok at prices in the region of US$40,000 and Thailands retirement visa foreigners could be a prize market though perhaps the Pattaya Expat Club may not have that many potential clients with such an amount of money spare.

GLOBAL STEM CELL NETWORK COMPANY LIMITED 210/3 SOI NA THONG DIN DAENG, KHET DIN DAENG, BANGKOK founded 30/06/2552 2M baht registered capital. 2 Thai shareholders with 61% + 1 American shareholder with 39% Given the number of firms crammed in, this address is probably virtual offices or an accountant's office.

Read the original here:
STEM CELL THERAPY IN BANGKOK - Andrew Drummond

JAX Mice Database – 014543 STOCK Hgf Prkdc …

Agerstam H; Jaras M; Andersson A; Johnels P; Hansen N; Lassen C; Rissler M; Gisselsson D; Olofsson T; Richter J; Fan X; Ehinger M; Fioretos T. 2010. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood 116(12):2103-11. [PubMed: 20554971] [MGI Ref ID J:164507]

Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F. 2008. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 123(9):2222-7. [PubMed: 18688847] [MGI Ref ID J:142410]

Ahsmann EJ; van Tol MJ; Oudeman-Gruber J; Lokhorst H; Uytdehaag FG; Schuurman HJ; Bloem AC. 1995. The SCID mouse as a model for multiple myeloma. Br J Haematol 89(2):319-27. [PubMed: 7873382] [MGI Ref ID J:22989]

Akiba H; Takeda K; Kojima Y; Usui Y; Harada N; Yamazaki T; Ma J; Tezuka K; Yagita H; Okumura K. 2005. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol 175(4):2340-8. [PubMed: 16081804] [MGI Ref ID J:107507]

Al-Qaoud KM; Fleischer B; Hoerauf A. 1998. The Xid defect imparts susceptibility to experimental murine filariosis--association with a lack of antibody and IL-10 production by B cells in response to phosphorylcholine. Int Immunol 10(1):17-25. [PubMed: 9488152] [MGI Ref ID J:110480]

Alba A; Puertas MC; Carrillo J; Planas R; Ampudia R; Pastor X; Bosch F; Pujol-Borrell R; Verdaguer J; Vives-Pi M. 2004. IFNbeta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice. J Immunol 173(11):6667-75. [PubMed: 15557158] [MGI Ref ID J:94366]

Alfaro MP; Pagni M; Vincent A; Atkinson J; Hill MF; Cates J; Davidson JM; Rottman J; Lee E; Young PP. 2008. The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A 105(47):18366-71. [PubMed: 19017790] [MGI Ref ID J:142215]

Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO. 2012. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a T-effector memory phenotype. PLoS One 7(8):e44219. [PubMed: 22937164] [MGI Ref ID J:191672]

Alugupalli KR; Gerstein RM; Chen J; Szomolanyi-Tsuda E; Woodland RT; Leong JM. 2003. The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes. J Immunol 170(7):3819-27. [PubMed: 12646649] [MGI Ref ID J:125443]

Ambrosino E; Spadaro M; Iezzi M; Curcio C; Forni G; Musiani P; Wei WZ; Cavallo F. 2006. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 66(15):7734-40. [PubMed: 16885376] [MGI Ref ID J:112102]

Read more from the original source:
JAX Mice Database - 014543 STOCK Hgf Prkdc ...

Stem Cell TV | Video / Media News

Our Technology Phoenix Stem Cell Treatment Center uses adipose derived stem cells for deployment & clinical research. Early stem cell research has traditionally been associated with the controversial use of embryonic stem cells Continue reading

Source Link(s) Are Here

What Is A Stem Cell, Stem Cell Questions, How Do Stem ...

Helga Kolb 1. General characteristics. At every level of the retina there are reciprocal or feed-back loops in the circuitry so that certain neurons can interact laterally within the same layer, vertically from one layer to the other and indeed from the brain to the retina. Continue reading

Source Link(s) Are Here

Feedback Loops by Helga Kolb Webvision

Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F. Continue reading

Source Link(s) Are Here

JAX Mice Database - 005557 NOD.Cg-Prkdc Il2rg

Abstract This study demonstrates the possibility of using sanitizing detergents based on natural products for the elimination and/or reduction of Aeromonas hydrophila biofilm formed on stainless steel surfaces. The goal of this work was to determine the reduction effect of sanitizing detergents containing essential oils of Thymus vulgaris (thyme) and Cymbopogon citratus (lemongrass) on biofilm formed by A. hydrophila on AISI 304 stainless steel coupons, using UHT skimmed milk as substratum Continue reading

Visit link:
Stem Cell TV | Video / Media News